This HTML5 document contains 203 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n12http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n8https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q44585456
rdf:type
wikibase:Item
schema:description
artikulong pang-agham 2012年學術文章 artykuł naukowy wetenschappelijk artikel bài báo khoa học מאמר מדעי 2012年学术文章 scientific article published on 29 June 2012 artículo científico publicado en 2012 articolo scientifico 2012年學術文章 научна статия artigo científico 2012 nî lūn-bûn บทความทางวิทยาศาสตร์ 2012年学术文章 мақолаи илмӣ artikull shkencor article scientific научни чланак artículu científicu наукова стаття, опублікована в червні 2012 2012年學術文章 სამეცნიერო სტატია 2012年学术文章 2012年學術文章 vědecký článek scientific article published on 29 June 2012 vetenskaplig artikel ২৯ জুন ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scienca artikolo επιστημονικό άρθρο vitenskapelig artikkel artikel ilmiah vedecký článok teaduslik artikkel wissenschaftlicher Artikel 2012년 논문 artigo científico article científic 2012年学术文章 naučni članak article scientifique videnskabelig artikel scientific article published on 29 June 2012 bilimsel makale tieteellinen artikkeli vitskapeleg artikkel научная статья 2012年学术文章 artigo científico 2012年の論文 2012年学术文章 مقالة علمية نشرت في 29 يونيو 2012 tudományos cikk articol științific 2012年學術文章 научни чланак
p:P577
wds:Q44585456-7AB8AA6E-0896-450A-A153-FCDC9FD51FE4
wdt:P577
2012-06-29T00:00:00Z
p:P2888
wds:Q44585456-42967CBE-4679-4109-B5FD-4DDBAA67BE1B
wdt:P2888
n8:s00428-012-1267-2
p:P2860
wds:Q44585456-0345940C-1DDF-4DE2-85E9-CF62E9303B7C wds:Q44585456-0628DD3F-ED83-46B4-9FEC-A83CC6A58B51 wds:Q44585456-0A7B20B0-E8FF-4B7B-AA89-37EE65919941 wds:Q44585456-10434412-0D35-4778-A1F0-0CEBB69BA453 wds:Q44585456-1B293D9E-AD49-4D27-83D6-770F9D139CD6 wds:Q44585456-38C3B978-417F-4E3B-8CE4-240903B53591 wds:Q44585456-4E4ECF7B-F33A-4E0D-B606-0966D711FB24 wds:Q44585456-4F9BC2FC-C9A8-49CA-9034-ED989DBA6304 wds:Q44585456-1E852B99-406A-4FB0-B85D-EC5970413386 wds:Q44585456-22D1E370-A3C0-44C9-9353-FBC7B811FA8E wds:Q44585456-24717993-5543-4D61-8520-C15A88A20F51 wds:Q44585456-28E502B8-833D-4F02-83A7-5455E95ACACB wds:Q44585456-31639B82-EC22-4D90-8F6B-68CC190962BA wds:Q44585456-32F0D962-86CE-4D31-8383-9A84D68C0DFC wds:Q44585456-35CB1CEC-43AF-4AED-85CA-2213F369C599 wds:Q44585456-7E627525-F2FB-4917-9554-1F9D2C395AAD wds:Q44585456-81D3673D-75F4-4207-8D39-FD419B443373 wds:Q44585456-91247848-1605-499F-AEFE-73EF1FB0BE13 wds:Q44585456-57857AD0-446E-40F7-A54C-B86BFC4FA584 wds:Q44585456-5B6488AA-3772-4E0E-A826-4636687CA8E6 wds:Q44585456-628B76C4-9CF9-4EA7-B69E-F1905E17674C wds:Q44585456-6C3256C3-42AC-4838-8F15-CC776D9AB423 wds:Q44585456-7766A616-2F19-4B63-B902-0B189F961A0F wds:Q44585456-BDBE75CD-DB8C-42E6-A507-D59F8F7589A0 wds:Q44585456-C8068E92-B3B5-4660-9F4A-4C9939C24F91 wds:Q44585456-CE6AEF67-48ED-4416-85EC-E08799A0AA70 wds:Q44585456-D143059A-2FA0-4210-AC5E-F1A664931608 wds:Q44585456-93C5E457-D661-483E-91F7-CDF1EA9897C4 wds:Q44585456-A0AACA32-9279-4BE4-96C6-19E9E90B595C wds:Q44585456-AFA7EBC3-4403-48E4-8D10-73603EFCBE22 wds:Q44585456-B169B0CF-875C-49AD-B86D-C1FBCBB1D604 wds:Q44585456-B2F5AFFD-B187-484B-9FEC-7C707D1F1329 wds:Q44585456-B581917F-6802-40E7-9DD1-933C942C3EA8 wds:Q44585456-F51923FB-6FBF-4778-822A-9C5391FF71B7 wds:Q44585456-F57071D4-8133-4C9B-8D3A-68DA22AB51D2 wds:Q44585456-F5FEA1FD-B0A6-4804-92E3-0D383CE686A4 wds:Q44585456-F85CE232-C647-4D6A-B65A-848D4CD7D182 wds:Q44585456-FB4BB609-7E8F-4283-A7B9-7F0521262EB9 wds:Q44585456-D9471FB5-DC8A-4BB3-9DFA-5E27D85F1A2F wds:Q44585456-E88247C8-BC20-4BEF-8925-7FBD41EA9E5C wds:Q44585456-EA3A56BE-EA55-4FC7-AADA-5E78FC43B7AE wds:Q44585456-EADBA66B-8A01-4CB7-9D44-10CCCF0BB5BB wds:Q44585456-EC47031C-866E-4071-B3C0-95FDCA40A295 wds:Q44585456-F157E81E-66B9-47FA-A23E-A145349EEDCF
wdt:P2860
wd:Q79484933 wd:Q46827615 wd:Q36678668 wd:Q80379623 wd:Q37877173 wd:Q34073138 wd:Q29615810 wd:Q54615372 wd:Q46850327 wd:Q80467723 wd:Q40295610 wd:Q72087415 wd:Q35581813 wd:Q35038068 wd:Q36983065 wd:Q42523855 wd:Q33605111 wd:Q35624814 wd:Q42458540 wd:Q27851582 wd:Q62604205 wd:Q54769172 wd:Q46614726 wd:Q53366750 wd:Q44038195 wd:Q40073729 wd:Q51727532 wd:Q33579653 wd:Q33715936 wd:Q34394358 wd:Q81463881 wd:Q83932022 wd:Q33790555 wd:Q43579660 wd:Q39636381 wd:Q24321567 wd:Q37187915 wd:Q42461980 wd:Q35861503 wd:Q33933626 wd:Q34679149 wd:Q27851414 wd:Q28243071 wd:Q34775344
p:P2093
wds:Q44585456-8CADCFCC-7ABF-4A2F-80F5-1595D3A92C3E wds:Q44585456-7FAECB69-1BF3-4194-A537-8C5F7894062C wds:Q44585456-7B23E84B-BEAA-4100-BE08-99ACD8CD0B99 wds:Q44585456-6225FE5F-3057-49BC-9BD9-5DE00C59A2B2 wds:Q44585456-53214475-EF8A-4D19-B054-0A4E8A541AD0 wds:Q44585456-55690A68-472C-47E3-892F-7F698B0ED2F1 wds:Q44585456-3F3751D1-05CF-460B-8C42-AD0247218978 wds:Q44585456-DBD883D4-BB74-49BA-9A81-C8ACF18A2CE3 wds:Q44585456-DAF8786E-CCBA-424C-B5EE-A200F67021E2 wds:Q44585456-D30704DA-7B1D-4564-83D6-5B56C73313F8 wds:Q44585456-C99B9489-F8E3-42A5-B607-DF91EDCACEB6 wds:Q44585456-AAFC0D3F-C1A5-427D-8F4C-5E9E8567A851
wdt:P2093
Chiara Cantaloni Mattia Barbareschi Alessia Caldara Renza Triolo Salvatore Girlando Nicola Decarli Lucia Veronica Cuorvo Enzo Galligioni Emma Bragantini Paolo Dalla Palma Antonella Ferro Elena Leonardi
rdfs:label
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
skos:prefLabel
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
schema:name
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
p:P50
wds:Q44585456-35241C25-72CC-4B17-AA36-11AF2BB61F0B
wdt:P50
wd:Q57302308
p:P1476
wds:Q44585456-D9030A57-AB30-4DC1-A77C-3A086B9E3C96
wdt:P1476
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
p:P304
wds:Q44585456-6B1A3E4C-0780-480E-972B-9DD293F8CAD5
wdt:P304
129-139
p:P31
wds:Q44585456-44D5D9FC-E864-48E0-903C-0667E98CF6E5
wdt:P31
wd:Q13442814
p:P921
wds:Q44585456-95F1DDEF-EAF7-493C-8D0F-807E36140728
wdt:P921
wd:Q412616
p:P698
wds:Q44585456-8EF9C2A1-A076-4598-A39B-61135A5AACEF
wdtn:P698
n13:22744290
wdt:P698
22744290
p:P1433
wds:Q44585456-FD952A50-50C7-4E64-AF39-B81FA50DBAC7
wdt:P1433
wd:Q19059548
p:P433
wds:Q44585456-71D9AAEE-1E17-4971-9E54-0A55129F1148
p:P478
wds:Q44585456-0ED6E68F-172D-4D48-B1F5-43FB368325DD
wdt:P433
2
wdt:P478
461
p:P356
wds:Q44585456-C880BD17-967E-4DD3-9BD9-10DAA1BDC099
wdtn:P356
n12:S00428-012-1267-2
wdt:P356
10.1007/S00428-012-1267-2